注射POC重建

POC Reconstitution of Injectable Drugs

出版日期: 2022年12月31日 | 出版商:

Greystone Research Associates | 英文 100 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

生物製品固有的不穩定性是一個直接影響藥物輸送領域的限制。治療性蛋白質必須在特殊條件下儲存或配製以保持從製造到配製的效力。液體蛋白藥物在配藥前應冷藏。或者，可以將蛋白質配製成粉末（凍乾），但必須在註射前重新配製。

本報告探討了注射劑 POC 中的重構，並概述了藥物重構，包括生物製劑趨勢、競爭格局和市場進入者概況。

內容

執行摘要
注射劑的 PoC 重構
藥物重組市場動態
重組 - 生物製藥生活事實
可注射藥物生態系統
設備設計的演變
組合因子
產品專用設備開發
推動特殊注射設備需求的因素
慢性病和自我管理
生物製劑的增長
處方藥
患者人口統計數據的變化
安全與合規
設備設計和創新
競爭格局
技術市場驅動力
用於 POC 重建的集成設備
雙腔墨盒
雙腔進樣器
雙腔注射器
可穿戴式自動偵察系統
設備評估
產品專用設備
特殊設備
OEM 設備
雙腔安全注射器
治療部分 - 數據和預測
激素替代
感染
代謝狀態
骨質疏鬆症
神經學
腫瘤學
再生醫學
其他療法部分
市場因素
設備產品策略
設備經濟學
產品品牌
直接面向消費者的銷售
管理式醫療的趨勢
公司簡介

簡介目錄

Product Code: RJD929K

“POC Reconstitution of Injectable Drugs ” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for reconstitution systems for injectable drug products . Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Engineered Injectables that Address Chronic Conditions

The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed. Alternatively, proteins can be formulated as powders (lyophilization) and must be reconstituted prior to injection. Historically, this was accomplished by including a disposable syringe and diluent vial for manual reconstitution. As the number of drugs developed for self-administration has grown, devices that integrate a reconstitution step with the injection step have gained traction. As biological drugs continue to grow in terms of therapeutics and total prescriptions, the impact of specialty devices will increase.

What You Will Learn:

What is the impact of lyophilized injectable drugs on today's therapeutic market, how are they packaged, and who markets them?

Who are the suppliers of integrated reconstitution devices, and what is their market impact?

What are the major factors driving the demand for integrated devices for injectable drug reconstitution?

What is the relative impact of integrated reconstitution systems to OEM or standalone reconstitution devices and how will this change by the end of the decade?

What are the essential design factors, material selection issues, technologies and market development issues for drug reconstitution systems and devices?

What is the role of integrated drug reconstitution systems on drug life cycle management?

What are the significant economic, technology, and regulatory factors affecting the market for injectable drugs and reconstitution systems in particular?